ClinicalTrials.gg
RecruitingNCT05638724MLC-RUpdated Feb 15, 2024

Munich Long COVID Registry for Children, Adolescents, and Adults

An observational study in Post-COVID Condition, sponsored by Technical University of Munich. Recruiting at 1 site in Germany. Per ClinicalTrials.gov, last updated 2024-02-15.

Sponsored by Technical University of Munich · Observational

How we know

From the registry’s dates

  • Started Jul 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany — 14 open to participants now, 17 under way, 2 of them phase 3. Post-Acute COVID-19 Syndrome · Germany.

Planned enrollment
2nd of 13
1,000 · median 130
Started
2022
with 8 others
Observational
13 of 41
4 open now
Primary completion
2027-07
later than 12 of 16 live
Registered
10th of 41
by date
Lead sponsor
3 of 41
Technical University of Munich

Among the 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany, this one is the 2nd largest by planned enrollment of the 13 observational ones that give a count, is one of 9 that started in 2022, is one of 13 observational ones, reaches primary completion later than 12 of the 16 other live ones, and was the 10th registered.

Post-Acute COVID-19 Syndrome

606 studies on the registry are indexed under Post-Acute COVID-19 Syndrome; 201 are open to participants now.

Browse Post-Acute COVID-19 Syndrome studies →

Open to participants now

14 of the 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 144 Post-Acute COVID-19 Syndrome studies recruiting now, 69 (48%) set no upper age limit and 53 (37%) stop at 75 or younger; 15 take children under 18; 39 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Post-Acute COVID-19 Syndrome with a site in Germany, or all of them as a file.
02

Study summary

The MLC-R aims to create a large-scale registry that provides data on epidemiology, phenotypes, and disease trajectories of and health care for Long COVID at any age in Germany, which can be used for future clinical trials.

Read the detailed description

Infections with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been observed in Germany since January 2020 and can result in acute coronavirus disease 2019 (COVID-19) as well as in long-term sequela, referred to as Long COVID. The umbrella term Long COVID comprises ongoing new SARS-CoV-2-associated symptoms later than four weeks from the onset of acute COVID-19. The term Post-COVID-Condition (PCC) was introduced by the WHO and stands for ongoing or new SARS-CoV-2-associated symptoms, which persisted for at least two months. These symptoms often include fatigue, brain fog, dyspnea, orthostatic intolerance, as well as exercise intolerance, with a worsening of symptoms after mild daily activities (post-exertional malaise, PEM). PCC can severely impair daily function, social participation, and health-related quality of life. The prevalence was estimated as up to 15% in infected people with pre-Omicron variants and lower with Omicron variants. Risk factors include female gender and pre-existing morbidity, with low risk in young children. The most severe form of PCC in people with initially mild or moderate COVID-19 is myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). The prevalence of ME/CFS was shown to increase in the context of the pandemic. While progress has been made in deciphering the pathogenesis of acute COVID-19, the mechanisms of Long COVID/PCC are poorly understood. Increasing evidence indicates that remaining viral particles, as well as inflammation, altered microcirculation, dysfunction of the autonomic nervous system, and/or autoimmunity, may contribute.

With the web-based German MLC-R, we aim at deep phenotyping of PCC, identification of subtypes and risk factors, describing trajectories of the disease and patient journeys, and providing clinical data for future clinical trials. Patients are also invited to contribute biosamples for future translational research.

03

Conditions studied

  • Post-COVID Condition

Keywords

  • Long COVID
  • Post-COVID
  • ME/CFS
  • CFS/ME
  • SARS-CoV-2
  • COVID-19
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with PCC

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

I. Written of the patient or legal guardian.

II. Confirmed SARS-CoV-2 vaccination and/or confirmed or probable SARS-CoV-2 infection: Positive SARS-CoV-2 polymerase chain reaction (PCR) or rapid antigen test (), documented probable COVID-19 (e.g., typical CT scan), probable COVID-19 with a history of high-risk contact, anti-SARS-CoV-2-N antibodies (and/or in non-vaccinated people -S-IgG antibodies) following probable COVID-19.

III. Additional ICD-10 codes: U09.9!V: Suspected post-COVID-19 condition, unspecified; U12.9!V: suspected adverse reactions to COVID-19 vaccine use, unspecified (post-COVIDvac condition).

Exclusion criteria

Exclusion Criteria:

  • Any subsequent medical data that question the diagnosis of PCC or post-COVIDvac condition
  • Clinical picture can be explained by another underlying disease.
  • Pregnancy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Phenotyping of Post-COVID condition: Medical History

    Routine assessment of the medical history, such as current and previous medication, vaccinations, comorbidities, and more, to achieve a profound and detailed Post-COVID condition phenotype.

    Time frame: 5 years

  2. Phenotyping of Post-COVID condition: Physical Examination

    Routine physical examination to achieve a profound and detailed Post-COVID condition phenotype.

    Time frame: 5 years

  3. Phenotyping of Post-COVID condition: Laboratory Parameters

    Measurement of a routine set of laboratory parameters including blood tests (cell count, C-reactive protein, organ function, immunoglobulins, antibodies, etc.) and urine/stool analysis (calprotectin, blood) to achieve a profound Post-COVID condition phenotype.

    Time frame: 5 years

  4. Phenotyping of Post-COVID condition: Functional Tests

    Technical exams (e.g. pulmonary function tests, electrocardiography, ultrasound, magnetic resonance imaging, etc.) will be performed as indicated to achieve a profound and detailed Post-COVID condition phenotype.

    Time frame: 5 years

Secondary outcomes

  1. Analyzation of numbers of physicians involved

    Patients' journeys will be analyzed in terms of the number of physicians involved

    Time frame: 5 years

  2. Evaluation of kind of spezializations of physicians involved

    Patients' journeys will be analyzed in terms of the kind of specializations of physicians involved

    Time frame: 5 years

  3. Evaluation of kind of the latency of symptoms

    Patients' journeys will be analyzed in terms of the kind of specializations of physicians involved

    Time frame: 5 years

  4. Evaluation of kind of the onset of therapy

    Patients' journeys will be analyzed in terms of the latency from symptom onset to initiation of therapy in months.

    Time frame: 5 years

  5. Definition of Sub-cohorts

    Sub-cohorts are identified using routine data. By means of e.g. trigger, disease severity (e.g. Bell score from the worst outcome with 0 points till the best outcome with 100 points), daily functioning (e.g. SF-36).

    Time frame: 5 years

  6. Prevalence of Comorbidities

    Prevalence of comorbidities of patients with Post-COVID condition will be analyzed.

    Time frame: 5 years

  7. Identification of Candidate Prognostic Markers

    Correlation of routine clinical data (e.g., medical history, routine laboratory, and physical examination) with clinical outcome (e.g., health-related quality of life, disease severity, and social participation).

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
  • MRI Chronic Fatigue Center for Young People (MCFC) Children's Hospital, Technical University of Munich & Munich Municipal Hospital
    Munich, Bavaria 80804, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Jul 2027, 60 months after the start.

Of 97 non-industry observational studies under Post-Acute COVID-19 Syndrome, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 39. This study's planned 60 months is above that.

Counting every sponsor, half of 104 studies reached it within 26 months; a quarter within 14 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 3, 2022
First posted
Dec 6, 2022
StartActual
Jul 20, 2022
Primary completionEst.
Jul 20, 2027
CompletionEst.
Jul 20, 2027
Last update
Feb 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05638724
Collaborators
Charite University, Berlin, Germany, Ruhr University of Bochum, Germany, Technical University of Dresden, Germany, University of Freiburg, University of Hamburg-Eppendorf, Leipniz University Hannover, Germany., Saarland University Homburg,Germany., Friedrich Schiller University Jena, Germany, University of Kassel, Germany., University of Cologne
Responsible party
Sponsor
First posted
Dec 6, 2022
Start date
Jul 20, 2022
Primary completion
Jul 20, 2027 (estimated)
Completion
Jul 20, 2027 (estimated)
Last update
Feb 15, 2024

Study contacts

Uta Behrends, Prof. Dr. med.
Contact
uta.behrends@tum.de
+4989 3068 2632
Daniela Schindler, Dr.
Contact
daniela.schindler@tum.de
+4989 4140 6995
Uta Behrends, Prof. Dr. med.
principal investigator · MRI Chronic Fatigue Center for Young People (MCFC), Children's Hospital, Technical University of Munich & Munich Municipal Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion